HMGA2 Human shRNA Plasmid Kit (Locus ID 8091)

Specifications

Product Data
Locus ID	8091
Synonyms	BABL; BABL, LIPO, HMGIC, HMGI-C; high-mobility group (nonhistone chromosomal) protein isoform I-C; High-mobility group protein HMGI-C; high mobility group AT-hook 2; HMGI-C; HMGIC; LIPO; STQTL9
Vector	pGFP-V-RS
E. coli Selection	Kanamycin
Mammalian Cell Selection	Puromycin
Format	Retroviral plasmids
Kit Components	HMGA2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 8091). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
RefSeq	NM_001015886, NM_001300918, NM_001300919, NM_001330190, NM_003483, NM_003484, NM_003483.1, NM_003483.2, NM_003483.3, NM_003483.4, NM_003484.1, NM_001300918.1, NM_001300919.1, NM_001015886.1, BC160115, BM782659, NM_003483.6
UniProt ID	P52926
Summary	This gene encodes a protein that belongs to the non-histone chromosomal high mobility group (HMG) protein family. HMG proteins function as architectural factors and are essential components of the enhancesome. This protein contains structural DNA-binding domains and may act as a transcriptional regulating factor. Identification of the deletion, amplification, and rearrangement of this gene that are associated with myxoid liposarcoma suggests a role in adipogenesis and mesenchymal differentiation. A gene knock out study of the mouse counterpart demonstrated that this gene is involved in diet-induced obesity. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@clinisciences.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@clinisciences.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).